Literature DB >> 23944319

Current and future therapies for hepatitis C virus infection.

Resat Ozaras, Mücahit Yemisen, İlker İ Balkan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23944319     DOI: 10.1056/NEJMc1307589

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Peginterferon Alfa-2a/Ribavirin treatment efficacy in chronic hepatitis C patients is related to natural killer group 2D gene rs1049174 GC polymorphism.

Authors:  Abolghasem Asadi-Saghandi; Ali Shams; Gilda Eslami; Seyed Ali Mirghanizadeh; Ebrahim Eskandari-Nasab
Journal:  Virusdisease       Date:  2016-09-28

2.  Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.

Authors:  Jingjing Wu; Peng Huang; Haozhi Fan; Ting Tian; Xueshan Xia; Zuqiang Fu; Yan Wang; Xiangyu Ye; Ming Yue; Yun Zhang
Journal:  Virol J       Date:  2019-01-17       Impact factor: 4.099

3.  Structurally distinct cyclosporin and sanglifehrin analogs CRV431 and NV556 suppress established HCV infection in humanized-liver mice.

Authors:  Michael Bobardt; Magnus Joakim Hansson; Patrick Mayo; Daren Ure; Robert Foster; Philippe Gallay
Journal:  PLoS One       Date:  2020-08-07       Impact factor: 3.240

4.  Prevalence and characteristics of hepatitis C virus infection in Shenyang City, Northeast China, and prediction of HCV RNA positivity according to serum anti-HCV level: retrospective review of hospital data.

Authors:  Yurong Li; Lianrong Zhao; Nan Geng; Weijia Zhu; Hongbo Liu; Han Bai
Journal:  Virol J       Date:  2020-03-16       Impact factor: 4.099

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.